Table 1 Patient characteristics (group A).

ID, patient number; G, gender; M, male; F, female; Std., standard cytogenetic risk [not 17p/tp53 altered or t(4;14), t(14;16)]; hetero, heterozygous p53 mutation/deletion; R-ISS, Revised Myeloma International Staging System; Imid, immunomodulatory class of drugs; PI, proteasome inhibitor class of drugs; MoAb, monoclonal antibody class of drugs; ASCT, number of prior autologous hematopoietic stem cell transplantations; DL, dose level; Y, yes; N, no.

IDAge/GR-ISS at
diagnosis
Cytogenetic riskNo. of
prior lines
Time to T
cells from
last therapy
Prior
Imid/PI/
MoAb?
No. of ASCTs
(time to
progression
after ASCT, if
applicable)
DLNo. of
infusions
TAA expression
at last biopsy
661/MIIStd.210 moY/Y/N118MAGE, NY-ESO-1,
SSX2, Survivin
744/MUnknownStd.25 moN/Y/N116Unavailable
857/MIIIStd.52.5 moY/Y/N2 (33 mo)22Unavailable
950/FIIStd.23 moY/Y/N124Unavailable
1153/MIIIStd.32 moY/Y/N128MAGE, PRAME,
Survivin
1254/MIStd.32 moY/Y/Y122MAGE, NY-ESO-1,
PRAME
1850/FIIIStd.59 moY/Y/Y2 (37 mo)32Unavailable
1970/MIII17p del (5% of all
marrow, hetero)
72 moY/Y/N2 (36 mo)34Unavailable
2163/MIStd.33 moY/Y/N132Unavailable